CSL (ASX:CSL) share price sinks 14% after reducing FY26 profit guidance
The CSL Ltd (ASX: CSL) share price is down more than 14% after holding its AGM and reducing guidance.
CSL is Australia’s largest biotechnology business, with vaccines and blood plasma being two of its key areas of focus.
CSL share price sinks on FY26 earnings downgrade
The company said that in its vaccine business, it has seen a greater decline in flu vaccination rates in the US than expected.
That’s despite a positive recommendation from the US administration on flu vaccines and an unprecedented level of infection impacting public health.
In the current Northern Hemisphere 2025/2026 season, based on insurance claims data to date, it’s now expecting US vaccination rates to decline by 12% for the overall population and 14%…
